NTLA vs EDIT
NTLA and EDIT side by side — valuation & fundamentals (public data).
Key statistics
| Metric | NTLAINTELLIA THERAPEUTICS, INC. | EDITEDITAS MEDICINE, INC. |
|---|---|---|
| Market cap | $1.72B | $416.97M |
| P/S | 25.4x | 10.3x |
| Revenue growth (YoY) | 16.9% | 25.4% |
| Earnings growth (YoY) | 20.5% | 32.5% |
| EBIT margin | -651.7% | -394.9% |
| ROE | -56.7% | -152.0% |
| 1y total return | -1.1% | -0.4% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: NTLA frente a EDIT
| Métrica | NTLA | EDIT |
|---|---|---|
| Valor final | $4.9K | $800 |
| Retorno total | -50.9% | -92.0% |
| CAGR | -6.7% | -21.7% |
| Volatilidad | 78.2% | 83.4% |
| Sharpe | 0.25 | 0.06 |
| Sortino | 0.37 | 0.09 |
| Caída máxima | -96.5% | -98.9% |
Basado en 2600 días de negociación comunes, 2016-05-16 → 2026-09-17 · tasa libre de riesgo 4.12% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)